sglt2 inhibitors and glp-1 receptor agonists together Comparative effectiveness of inhibitors, agonists, DPP-4 inhibitors, sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records b3 Quantity:Triple-Pack ($99) Obesity medicine for eligible

sglt2 inhibitors and glp-1 receptor agonists together Comparative effectiveness of inhibitors, agonists, DPP-4 inhibitors, sulfonylureas on risk of major adverse cardiovascular events: emulation of a randomised target trial using electronic health records b3 Quantity:Triple-Pack ($99) Obesity medicine for eligible

Obesity medicine for eligible Medicare Part D patients is now covered through the Medicare GLP-1 Bridge program. Because medicine only matters if the people who need it can get it. #WeAreLilly

N Engl J Med (2011) 364:829–41

b3

Quantity:Triple-Pack ($99)

doi: 10.1016/j.molmet.2024.101880 244 Re CecconiADBaroneMFortiMLunardiMCagnottoASalmonaMet al